APG Asset Management N.V. Buys 59,984 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

APG Asset Management N.V. raised its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 275.5% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 81,755 shares of the biopharmaceutical company's stock after buying an additional 59,984 shares during the quarter. APG Asset Management N.V. owned 0.07% of Regeneron Pharmaceuticals worth $56,240,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in REGN. Rakuten Securities Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 62.5% in the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 15 shares during the period. OFI Invest Asset Management acquired a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $28,000. Avalon Trust Co bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $36,000. Crowley Wealth Management Inc. acquired a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at $36,000. Finally, Private Wealth Management Group LLC lifted its position in Regeneron Pharmaceuticals by 260.0% in the fourth quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company's stock worth $38,000 after purchasing an additional 39 shares during the period. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Price Performance

REGN traded up $9.60 on Monday, hitting $563.78. 323,713 shares of the stock were exchanged, compared to its average volume of 706,254. The firm has a market capitalization of $61.64 billion, a price-to-earnings ratio of 14.73, a PEG ratio of 2.34 and a beta of 0.44. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. Regeneron Pharmaceuticals, Inc. has a 12 month low of $525.99 and a 12 month high of $1,211.20. The business has a 50-day moving average of $659.94 and a two-hundred day moving average of $753.23.

Remove Ads

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping analysts' consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter in the prior year, the firm posted $11.86 EPS. The firm's quarterly revenue was up 10.3% on a year-over-year basis. Sell-side analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were issued a dividend of $0.88 per share. The ex-dividend date was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.62%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 2.30%.

Wall Street Analyst Weigh In

REGN has been the subject of several recent research reports. JPMorgan Chase & Co. dropped their price target on shares of Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an "overweight" rating for the company in a research report on Monday, March 31st. Leerink Partnrs upgraded Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, February 5th. Bernstein Bank decreased their price target on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. Leerink Partners raised Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and lifted their price objective for the company from $762.00 to $834.00 in a report on Wednesday, February 5th. Finally, Citigroup lowered their target price on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating on the stock in a report on Tuesday, January 28th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $966.88.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.